Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Research & Development (2017 - 2025)

Sutro Biopharma's Research & Development history spans 9 years, with the latest figure at $39.9 million for Q3 2025.

  • For Q3 2025, Research & Development fell 35.83% year-over-year to $39.9 million; the TTM value through Sep 2025 reached $200.8 million, down 14.46%, while the annual FY2024 figure was $252.0 million, 39.69% up from the prior year.
  • Research & Development for Q3 2025 was $39.9 million at Sutro Biopharma, up from $38.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $71.0 million in Q4 2024 and bottomed at $22.6 million in Q1 2021.
  • The 5-year median for Research & Development is $39.9 million (2025), against an average of $42.3 million.
  • The largest annual shift saw Research & Development skyrocketed 49.12% in 2024 before it crashed 38.21% in 2025.
  • A 5-year view of Research & Development shows it stood at $29.9 million in 2021, then skyrocketed by 44.13% to $43.1 million in 2022, then increased by 24.64% to $53.8 million in 2023, then surged by 32.12% to $71.0 million in 2024, then crashed by 43.9% to $39.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Research & Development are $39.9 million (Q3 2025), $38.3 million (Q2 2025), and $51.6 million (Q1 2025).